P1276: DOSE RESPONSE PROFILE OF IGM-2323, A CD20XCD3 IGM BISPECIFIC T CELL ENGAGER, IN TRANSLATIONAL MODELS SUPPORTS PHASE 2 DOSE SELECTION IN NON-HODGKIN’S LYMPHOMA - M. K. Leabman; G. Hernandez; C. M. Ng; J. Tang; D. Pandya; K. C. Hart; K. Li; P. R. Hinton; J. So; I. Qazi; C. Y. Cheah; W. S. Kim; et al. (HemaSphere, 2022)